Search

Displaying results 9721 - 9730 of 10000 in total
  1. Drug

    Rilvegostomig

    go.drugbank.com/drugs/DB18991
    Investigational

    Rilvegostomig is under investigation in clinical trial NCT06109779 (Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (Artemide-biliary01)).

  2. Drug

    Zelquistinel

    go.drugbank.com/drugs/DB19336
    Investigational

    Zelquistinel is under investigation in clinical trial NCT06547489 (GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder).

  3. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

  4. Drug

    LLL-3348

    go.drugbank.com/drugs/DB05771
    Experimental

    The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.

  5. Drug

    CRA-028129

    go.drugbank.com/drugs/DB05951
    Experimental

    CRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.

  6. Drug

    Tonabersat

    go.drugbank.com/drugs/DB06578
    Investigational

  7. Drug

    FG-2216

    go.drugbank.com/drugs/DB08687
    Investigational

    A orally active prolyl-hydroxylase inhibitor which can stabilize hypoxia-inducible transcription factor independent of oxygen availability.

    Synonyms: 1-Chloro-N- (hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide, 1-Chloro-N-(hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide
  8. Drug

    PM02734

    go.drugbank.com/drugs/DB05158
    Investigational

    PM02734 is a marine derived compound. PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.

  9. Drug

    Valomaciclovir

    go.drugbank.com/drugs/DB06575
    Investigational

  10. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]